A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes

V Hutchins, B Zhang, RL Fleurence… - … medical research and …, 2011 - Taylor & Francis
Objective: Oral antidiabetics have comparable safety and efficacy when used as fixed-dose
combination therapies (FDCT) or loose-pill combination therapies (LPCT) for patients with …

Sensitivity analysis in cost-effectiveness studies: from guidelines to practice

R Jain, M Grabner, E Onukwugha - Pharmacoeconomics, 2011 - Springer
Cost-effectiveness analysis (CEA) is one of the main tools of economic evaluation. Every
CEA is based on a number of assumptions, some of which may not be accurate, introducing …

The CORE Diabetes Model: projecting long-term clinical outcomes, costs and costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical …

AJ Palmer, S Roze, WJ Valentine… - … medical research and …, 2004 - Taylor & Francis
Objectives: We have developed an Internet-based, interactive computer model to determine
the longterm health outcomes and economic consequences of implementing different …

Discrete event simulation: the preferred technique for health economic evaluations?

JJ Caro, J Möller, D Getsios - Value in health, 2010 - Elsevier
Objectives To argue that discrete event simulation should be preferred to cohort Markov
models for economic evaluations in health care. Methods The basis for the modeling …

[PDF][PDF] Papel de los modelos en las evaluaciones económicas en el campo sanitario

JMR Barrios - Farm Hosp, 2004 - sefh.es
Introducción: La información que sustenta las decisiones en sanidad, especialmente la
relativa al uso de nuevos fármacos o tecnologías, está basada en ensayos clínicos fase III …

Drugs for rare disorders

S Cremers, JK Aronson - British Journal of Clinical …, 2017 - Wiley Online Library
Estimates of the frequencies of rare disorders vary from country to country; the global
average defined prevalence is 40 per 100 000 (0.04%). Some occur in only one or a few …

The generalisability of pharmacoeconomic studies: issues and challenges ahead

JM Mason, AR Mason - Pharmacoeconomics, 2006 - Springer
Developing from a previous review, this article revisits the generalisability theme to
summarise recent advances in methodology and provide an update of challenges faced by …

Sağlık ekonomisi perspektifinden farmakoekonomi

A Acar, S Yeğenoğlu - Hacettepe University Journal of the Faculty of …, 2006 - dergipark.org.tr
Ülkelerin gittikçe artan sağlık harcamaları karşısında kaynakların sınırlı olması, sağlık
ekonomisinin ve bir alt dalı olarak farmakoekonominin ortaya çıkmasına neden olmuştur …

Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype

L Hörster, RF Schlenk, M Stadler, M Gabriel, F Thol… - Leukemia Research, 2017 - Elsevier
Background During the last years, molecular genetic data are increasingly used as
prognostic and predictive factors in acute myeloid leukemia (AML). The molecular genetic …

[PDF][PDF] Cost-effectiveness analysis

P LeBel - Center for Economic Research on Africa. Monclair …, 2011 - msuweb.montclair.edu
The choice of a development project depends in part on the underlying financial framework.
Projects that are purely private in nature can generally be classified in terms of their …